Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Inokuchi, M, Yamashita, T, Yamada, H, Kojima, K, Ichikawa, W, Nihei, Z, Kawano, T, Sugihara, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361252/
https://www.ncbi.nlm.nih.gov/pubmed/16570038
http://dx.doi.org/10.1038/sj.bjc.6603072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361252/
https://www.ncbi.nlm.nih.gov/pubmed/16570038
http://dx.doi.org/10.1038/sj.bjc.6603072

Ejemplares similares